Literature DB >> 24167680

Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.

Matthias Kirschner1, Anastasia Theodoridou, Paolo Fusar-Poli, Stefan Kaiser, Matthias Jäger.   

Abstract

OBJECTIVES: The acceptance and use of long-acting depot antipsychotics has been shown to be influenced by the attitudes of patients and clinicians. Depot treatment rates are low across countries and especially patients with first-episode psychosis are rarely treated with depot medication. The aim of this article was to review the literature on patients' and clinicians' attitudes towards long-acting depot antipsychotics in subjects with first-episode psychosis.
METHODS: A systematic search of Medline, Embase, PsycINF and Google Scholar was conducted. Studies were included if they reported original data describing patients' and clinicians' attitudes towards long-acting depot antipsychotic in subjects with first-episode psychosis.
RESULTS: Six studies out of a total of 503 articles met the inclusion criteria. Four studies conveyed a negative and two a positive opinion of clinicians toward depot medication. No systematic study directly addressed the attitude of patients with first-episode psychosis. Psychiatrists frequently presume that patients with first-episode psychosis would not accept depot medication and that depots are mostly eligible for chronic patients.
CONCLUSIONS: Full information of all patients especially those with first episode psychosis in a therapeutic relationship that includes shared decision-making processes could reduce the negative image and stigmatization attached to depots.

Entities:  

Keywords:  antipsychotics; attitudes; depot; first-episode psychosis; schizophrenia

Year:  2013        PMID: 24167680      PMCID: PMC3805393          DOI: 10.1177/2045125312464106

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  48 in total

Review 1.  Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.

Authors:  D A Johnson
Journal:  J Clin Psychiatry       Date:  1984-05       Impact factor: 4.384

2.  Attitudes of psychiatrists toward antipsychotic depot medication.

Authors:  Stephan Heres; Johannes Hamann; Werner Kissling; Stefan Leucht
Journal:  J Clin Psychiatry       Date:  2006-12       Impact factor: 4.384

3.  Effect of medication-related factors on adherence in people with schizophrenia: a European multi-centre study.

Authors:  Johanna Meier; Thomas Becker; Anita Patel; Debbie Robson; Aart Schene; Martijn Kikkert; Corrado Barbui; Lorenzo Burti; Bernd Puschner
Journal:  Epidemiol Psichiatr Soc       Date:  2010 Jul-Sep

4.  Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.

Authors:  J M Kane; E Aguglia; A C Altamura; J L Ayuso Gutierrez; N Brunello; W W Fleischhacker; W Gaebel; J Gerlach; J D Guelfi; W Kissling; Y D Lapierre; E Lindström; J Mendlewicz; G Racagni; L S Carulla; N R Schooler
Journal:  Eur Neuropsychopharmacol       Date:  1998-02       Impact factor: 4.600

5.  Systematic review of patient and nurse attitudes to depot antipsychotic medication.

Authors:  J Walburn; R Gray; K Gournay; S Quraishi; A S David
Journal:  Br J Psychiatry       Date:  2001-10       Impact factor: 9.319

6.  Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

Authors:  Matthias Jaeger; Wulf Rossler
Journal:  Psychiatry Res       Date:  2009-12-11       Impact factor: 3.222

7.  Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years.

Authors:  M X Patel; P M Haddad; I B Chaudhry; S McLoughlin; N Husain; A S David
Journal:  J Psychopharmacol       Date:  2009-05-28       Impact factor: 4.153

8.  Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis.

Authors:  Stephan Heres; Johannes Hamann; Rosmarie Mendel; Florian Wickelmaier; Frank-Gerald Pajonk; Stefan Leucht; Werner Kissling
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-10-09       Impact factor: 5.067

Review 9.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

10.  The cost of relapse and the predictors of relapse in the treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; David Salkever; Eric P Slade; Xiaomei Peng; Robert R Conley
Journal:  BMC Psychiatry       Date:  2010-01-07       Impact factor: 3.630

View more
  26 in total

1.  A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections.

Authors:  Amlan K Das; Abid Malik; Peter M Haddad
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability.

Authors:  Sourabh Moti Singh; Peter M Haddad; Nusrat Husain; Eamonn Heaney; Barbara Tomenson; Imran B Chaudhry
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

Review 3.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

4.  Can a digital medicine system improve adherence to antipsychotic treatment?

Authors:  D Papola; C Gastaldon; G Ostuzzi
Journal:  Epidemiol Psychiatr Sci       Date:  2018-03-12       Impact factor: 6.892

5.  Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study.

Authors:  Armando D'Agostino; Andrea Aguglia; Corrado Barbui; Francesco Bartoli; Giuseppe Carrà; Simone Cavallotti; Margherita Chirico; Edoardo G Ostinelli; Caroline Zangani; Giovanni Martinotti; Giovanni Ostuzzi
Journal:  BMC Psychiatry       Date:  2022-06-30       Impact factor: 4.144

Review 6.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

7.  Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.

Authors:  Dee Lin; Philippe Thompson-Leduc; Isabelle Ghelerter; Ha Nguyen; Marie-Hélène Lafeuille; Carmela Benson; Panagiotis Mavros; Patrick Lefebvre
Journal:  CNS Drugs       Date:  2021-04-28       Impact factor: 5.749

Review 8.  Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review.

Authors:  Alexandre González-Rodríguez; Rosa Catalán; Rafael Penadés; Clemente Garcia-Rizo; Miquel Bioque; Eduard Parellada; Miquel Bernardo
Journal:  Patient Prefer Adherence       Date:  2015-05-25       Impact factor: 2.711

Review 9.  Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Authors:  Georgia L Stevens; Gail Dawson; Jacqueline Zummo
Journal:  Early Interv Psychiatry       Date:  2015-09-25       Impact factor: 2.732

10.  Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics.

Authors:  Andrea de Bartolomeis; Andrea Fagiolini; Marco Vaggi; Claudio Vampini
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-11       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.